FDA Clears Next-Generation Guide Wire for Cardiovascular Systems’ Peripheral Orbital Atherectomy Systems



ST. PAUL, Minn.–(EON: Enhanced Online News)–Cardiovascular Systems, Inc. (NASDAQ:CSII) (CSI), today announced that it has received FDA clearance for its new ViperWire Advance® Peripheral Guide Wire with Flex Tip for their Peripheral Orbital Atherectomy Systems (OAS). The new guide wire provides physicians with improved flexibility, navigation and ease-of-use—particularly in hard-to-reach, tortuous vessels—when treating arterial calcium associated with peripheral artery disease (PAD). read more

Celprogen Introduces Xeno-Free Serum Substitute [XFS2], an Ideal Cell Culture Product for Propagating Stem Cells, Progenitor Cells, Induced Pluripotent Cells and Primary Human Cells for Clinical Applications

TORRANCE, Calif.–(EON: Enhanced Online News)–Celprogen Inc., a leader in the Stem Cell Research and Therapeutics industry committed to providing high quality stem cell technologies for regenerative medicine, today announced that they have developed a novel Xeno-Free Serum Substitute [XFS2] cell culture media product for human cell culture systems. XFS2 product (Catalog number MX7777-15) can be utilized for culturing stem cells, progenitor cells, induced pluripotent cells and primary human cells for clinical application. The product can also be utilized for culturing cancer stem cells, circulating tumor cells and differentiated parental tumor cells for basic science research in Oncology. read more

Thoratec Announces First HeartMate 3™ Implant in European Less Invasive Surgical Trial

PLEASANTON, Calif., July 6, 2015 /PRNewswire/ — Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced the first ever HeartMate 3™ implant performed via mini-thoracotomy.  This implant begins a European study to evaluate outcomes and complications using less invasive surgical placement through hemi-sternotomy and left thoracotomy techniques.  The study will include ten cases performed at three European centers following one initial case to build experience at each center, and will measure the outcomes specified in the HeartMate 3 CE Mark trial after 30 days of follow-up. read more


Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.